Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Simultaneous Deletion of Endogenous TCRαβ for TCR Gene Therapy Creates an Improved and Safe Cellular Therapeutic.

Morton LT, Reijmers RM, Wouters AK, Kweekel C, Remst DFG, Pothast CR, Falkenburg JHF, Heemskerk MHM.

Mol Ther. 2019 Oct 4. pii: S1525-0016(19)30455-1. doi: 10.1016/j.ymthe.2019.10.001. [Epub ahead of print]

PMID:
31636040
2.

Framework engineering to produce dominant T cell receptors with enhanced antigen-specific function.

Thomas S, Mohammed F, Reijmers RM, Woolston A, Stauss T, Kennedy A, Stirling D, Holler A, Green L, Jones D, Matthews KK, Price DA, Chain BM, Heemskerk MHM, Morris EC, Willcox BE, Stauss HJ.

Nat Commun. 2019 Oct 1;10(1):4451. doi: 10.1038/s41467-019-12441-w.

3.

Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile.

Krijgsman D, de Vries NL, Skovbo A, Andersen MN, Swets M, Bastiaannet E, Vahrmeijer AL, van de Velde CJH, Heemskerk MHM, Hokland M, Kuppen PJK.

Cancer Immunol Immunother. 2019 Jun;68(6):1011-1024. doi: 10.1007/s00262-019-02343-7. Epub 2019 May 3.

4.

Peripheral and systemic antigens elicit an expandable pool of resident memory CD8+ T cells in the bone marrow.

Pascutti MF, Geerman S, Collins N, Brasser G, Nota B, Stark R, Behr F, Oja A, Slot E, Panagioti E, Prier JE, Hickson S, Wolkers MC, Heemskerk MHM, Hombrink P, Arens R, Mackay LK, van Gisbergen KPJM, Nolte MA.

Eur J Immunol. 2019 Jun;49(6):853-872. doi: 10.1002/eji.201848003. Epub 2019 Apr 2.

5.

Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.

van der Lee DI, Reijmers RM, Honders MW, Hagedoorn RS, de Jong RC, Kester MG, van der Steen DM, de Ru AH, Kweekel C, Bijen HM, Jedema I, Veelken H, van Veelen PA, Heemskerk MH, Falkenburg JHF, Griffioen M.

J Clin Invest. 2019 Feb 1;129(2):774-785. doi: 10.1172/JCI97482. Epub 2019 Jan 14.

6.

PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy.

Luk SJ, van der Steen DM, Hagedoorn RS, Jordanova ES, Schilham MW, Bovée JV, Cleven AH, Falkenburg JF, Szuhai K, Heemskerk MH.

Oncoimmunology. 2018 Sep 11;7(12):e1507600. doi: 10.1080/2162402X.2018.1507600. eCollection 2018.

7.

Identification of non-mutated neoantigens presented by TAP-deficient tumors.

Marijt KA, Blijleven L, Verdegaal EME, Kester MG, Kowalewski DJ, Rammensee HG, Stevanović S, Heemskerk MHM, van der Burg SH, van Hall T.

J Exp Med. 2018 Sep 3;215(9):2325-2337. doi: 10.1084/jem.20180577. Epub 2018 Aug 16.

8.

microRNA 125a Regulates MHC-I Expression on Esophageal Adenocarcinoma Cells, Associated With Suppression of Antitumor Immune Response and Poor Outcomes of Patients.

Mari L, Hoefnagel SJM, Zito D, van de Meent M, van Endert P, Calpe S, Sancho Serra MDC, Heemskerk MHM, van Laarhoven HWM, Hulshof MCCM, Gisbertz SS, Medema JP, van Berge Henegouwen MI, Meijer SL, Bergman JJGHM, Milano F, Krishnadath KK.

Gastroenterology. 2018 Sep;155(3):784-798. doi: 10.1053/j.gastro.2018.06.030. Epub 2018 Jun 7.

PMID:
29885883
9.

A Jurkat 76 based triple parameter reporter system to evaluate TCR functions and adoptive T cell strategies.

Rosskopf S, Leitner J, Paster W, Morton LT, Hagedoorn RS, Steinberger P, Heemskerk MHM.

Oncotarget. 2018 Apr 3;9(25):17608-17619. doi: 10.18632/oncotarget.24807. eCollection 2018 Apr 3.

10.

Adoptive Immunotherapy Using PRAME-Specific T Cells in Medulloblastoma.

Orlando D, Miele E, De Angelis B, Guercio M, Boffa I, Sinibaldi M, Po A, Caruana I, Abballe L, Carai A, Caruso S, Camera A, Moseley A, Hagedoorn RS, Heemskerk MHM, Giangaspero F, Mastronuzzi A, Ferretti E, Locatelli F, Quintarelli C.

Cancer Res. 2018 Jun 15;78(12):3337-3349. doi: 10.1158/0008-5472.CAN-17-3140. Epub 2018 Apr 3.

11.

Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs.

Bijen HM, van der Steen DM, Hagedoorn RS, Wouters AK, Wooldridge L, Falkenburg JHF, Heemskerk MHM.

Mol Ther. 2018 May 2;26(5):1206-1214. doi: 10.1016/j.ymthe.2018.02.017. Epub 2018 Feb 23.

12.

HLA Class I Antigen Expression in Conjunctival Melanoma Is Not Associated With PD-L1/PD-1 Status.

Cao J, Brouwer NJ, Jordanova ES, Marinkovic M, van Duinen SG, de Waard NE, Ksander BR, Mulder A, Claas FHJ, Heemskerk MHM, Jager MJ.

Invest Ophthalmol Vis Sci. 2018 Feb 1;59(2):1005-1015. doi: 10.1167/iovs.17-23209.

PMID:
29450544
13.

Specific T Cell Responses against Minor Histocompatibility Antigens Cannot Generally Be Explained by Absence of Their Allelic Counterparts on the Cell Surface.

Bijen HM, Hassan C, Kester MGD, Janssen GMC, Hombrink P, de Ru AH, Drijfhout JW, Meiring HD, de Jong AP, Falkenburg JHF, Jimenez CR, Heemskerk MHM, van Veelen PA.

Proteomics. 2018 Jun;18(12):e1700250. doi: 10.1002/pmic.201700250. Epub 2018 Feb 23.

PMID:
29251415
14.

PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.

Gezgin G, Luk SJ, Cao J, Dogrusöz M, van der Steen DM, Hagedoorn RS, Krijgsman D, van der Velden PA, Field MG, Luyten GPM, Szuhai K, Harbour JW, Jordanova ES, Heemskerk MHM, Jager MJ.

JAMA Ophthalmol. 2017 Jun 1;135(6):541-549. doi: 10.1001/jamaophthalmol.2017.0729.

15.

Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response.

van Bergen CA, van Luxemburg-Heijs SA, de Wreede LC, Eefting M, von dem Borne PA, van Balen P, Heemskerk MH, Mulder A, Claas FH, Navarrete MA, Honders WM, Rutten CE, Veelken H, Jedema I, Halkes CJ, Griffioen M, Falkenburg JH.

J Clin Invest. 2017 Feb 1;127(2):517-529. doi: 10.1172/JCI86175. Epub 2017 Jan 9.

16.

TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1.

Jahn L, Hombrink P, Hagedoorn RS, Kester MG, van der Steen DM, Rodriguez T, Pentcheva-Hoang T, de Ru AH, Schoonakker MP, Meeuwsen MH, Griffioen M, van Veelen PA, Falkenburg JH, Heemskerk MH.

Blood. 2017 Mar 9;129(10):1284-1295. doi: 10.1182/blood-2016-09-737536. Epub 2017 Jan 4.

PMID:
28053195
17.

Pulmonary immune responses against Aspergillus fumigatus are characterized by high frequencies of IL-17 producing T-cells.

Jolink H, de Boer R, Hombrink P, Jonkers RE, van Dissel JT, Falkenburg JH, Heemskerk MH.

J Infect. 2017 Jan;74(1):81-88. doi: 10.1016/j.jinf.2016.10.010. Epub 2016 Nov 9.

PMID:
27838522
18.

Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies.

Jahn L, van der Steen DM, Hagedoorn RS, Hombrink P, Kester MG, Schoonakker MP, de Ridder D, van Veelen PA, Falkenburg JH, Heemskerk MH.

Oncotarget. 2016 Nov 22;7(47):77021-77037. doi: 10.18632/oncotarget.12778.

19.

A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer.

Jahn L, Hagedoorn RS, van der Steen DM, Hombrink P, Kester MG, Schoonakker MP, de Ridder D, van Veelen PA, Falkenburg JH, Heemskerk MH.

Oncotarget. 2016 Nov 1;7(44):71536-71547. doi: 10.18632/oncotarget.12247.

20.

CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses.

Hutten TJ, Thordardottir S, Fredrix H, Janssen L, Woestenenk R, Tel J, Joosten B, Cambi A, Heemskerk MH, Franssen GM, Boerman OC, Bakker LB, Jansen JH, Schaap N, Dolstra H, Hobo W.

J Immunol. 2016 Oct 1;197(7):2715-25. doi: 10.4049/jimmunol.1600011. Epub 2016 Aug 26.

21.

Uptake of HLA Alloantigens via CD89 and CD206 Does Not Enhance Antigen Presentation by Indirect Allorecognition.

Breman E, Ruben JM, Franken KL, Heemskerk MH, Roelen DL, Claas FH, van Kooten C.

J Immunol Res. 2016;2016:4215684. doi: 10.1155/2016/4215684. Epub 2016 Jun 20.

22.

The Epstein-Barr Virus Glycoprotein gp150 Forms an Immune-Evasive Glycan Shield at the Surface of Infected Cells.

Gram AM, Oosenbrug T, Lindenbergh MF, Büll C, Comvalius A, Dickson KJ, Wiegant J, Vrolijk H, Lebbink RJ, Wolterbeek R, Adema GJ, Griffioen M, Heemskerk MH, Tscharke DC, Hutt-Fletcher LM, Wiertz EJ, Hoeben RC, Ressing ME.

PLoS Pathog. 2016 Apr 14;12(4):e1005550. doi: 10.1371/journal.ppat.1005550. eCollection 2016 Apr.

23.

Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma.

Spel L, Boelens JJ, van der Steen DM, Blokland NJ, van Noesel MM, Molenaar JJ, Heemskerk MH, Boes M, Nierkens S.

Oncotarget. 2015 Nov 3;6(34):35770-81. doi: 10.18632/oncotarget.5657.

24.

T helper 2 response in allergic bronchopulmonary aspergillosis is not driven by specific Aspergillus antigens.

Jolink H, de Boer R, Willems LN, van Dissel JT, Falkenburg JH, Heemskerk MH.

Allergy. 2015 Oct;70(10):1336-9. doi: 10.1111/all.12688. Epub 2015 Aug 6.

PMID:
26179335
25.

Cytomegalovirus-Induced Expression of CD244 after Liver Transplantation Is Associated with CD8+ T Cell Hyporesponsiveness to Alloantigen.

de Mare-Bredemeijer EL, Shi XL, Mancham S, van Gent R, van der Heide-Mulder M, de Boer R, Heemskerk MH, de Jonge J, van der Laan LJ, Metselaar HJ, Kwekkeboom J.

J Immunol. 2015 Aug 15;195(4):1838-48. doi: 10.4049/jimmunol.1500440. Epub 2015 Jul 13.

26.

Design and validation of conditional ligands for HLA-B*08:01, HLA-B*15:01, HLA-B*35:01, and HLA-B*44:05.

Frøsig TM, Yap J, Seremet T, Lyngaa R, Svane IM, Thor Straten P, Heemskerk MH, Grotenbreg GM, Hadrup SR.

Cytometry A. 2015 Oct;87(10):967-75. doi: 10.1002/cyto.a.22689. Epub 2015 Jun 1.

27.

Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte-Derived HLA-Ligandome Using a Reverse Immunology Approach.

Hombrink P, Hassan C, Kester MG, Jahn L, Pont MJ, de Ru AH, van Bergen CA, Griffioen M, Falkenburg JH, van Veelen PA, Heemskerk MH.

Clin Cancer Res. 2015 May 1;21(9):2177-86. doi: 10.1158/1078-0432.CCR-14-2188. Epub 2015 Jan 14.

28.

Naturally processed non-canonical HLA-A*02:01 presented peptides.

Hassan C, Chabrol E, Jahn L, Kester MG, de Ru AH, Drijfhout JW, Rossjohn J, Falkenburg JH, Heemskerk MH, Gras S, van Veelen PA.

J Biol Chem. 2015 Jan 30;290(5):2593-603. doi: 10.1074/jbc.M114.607028. Epub 2014 Dec 12.

29.

The molecular bases of δ/αβ T cell-mediated antigen recognition.

Pellicci DG, Uldrich AP, Le Nours J, Ross F, Chabrol E, Eckle SB, de Boer R, Lim RT, McPherson K, Besra G, Howell AR, Moretta L, McCluskey J, Heemskerk MH, Gras S, Rossjohn J, Godfrey DI.

J Exp Med. 2014 Dec 15;211(13):2599-615. doi: 10.1084/jem.20141764. Epub 2014 Dec 1.

30.

Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b.

Jahn L, Hombrink P, Hassan C, Kester MG, van der Steen DM, Hagedoorn RS, Falkenburg JH, van Veelen PA, Heemskerk MH.

Blood. 2015 Feb 5;125(6):949-58. doi: 10.1182/blood-2014-07-587840. Epub 2014 Nov 20.

PMID:
25414443
31.

Cognate CD4 T-cell licensing of dendritic cells heralds anti-cytomegalovirus CD8 T-cell immunity after human allogeneic umbilical cord blood transplantation.

Flinsenberg TW, Spel L, Jansen M, Koning D, de Haar C, Plantinga M, Scholman R, van Loenen MM, Nierkens S, Boon L, van Baarle D, Heemskerk MH, Boelens JJ, Boes M.

J Virol. 2015 Jan 15;89(2):1058-69. doi: 10.1128/JVI.01850-14. Epub 2014 Nov 5.

32.

Accurate quantitation of MHC-bound peptides by application of isotopically labeled peptide MHC complexes.

Hassan C, Kester MG, Oudgenoeg G, de Ru AH, Janssen GM, Drijfhout JW, Spaapen RM, Jiménez CR, Heemskerk MH, Falkenburg JH, van Veelen PA.

J Proteomics. 2014 Sep 23;109:240-4. doi: 10.1016/j.jprot.2014.07.009. Epub 2014 Jul 19.

PMID:
25050860
33.

HLA monomers as a tool to monitor indirect allorecognition.

Breman E, van Miert PP, van der Steen DM, Heemskerk MH, Doxiadis II, Roelen D, Claas FH, van Kooten C.

Transplantation. 2014 Jun 15;97(11):1119-27. doi: 10.1097/TP.0000000000000113.

34.

Induction of A. fumigatus-specific CD4-positive T cells in patients recovering from invasive aspergillosis.

Jolink H, Hagedoorn RS, Lagendijk EL, Drijfhout JW, van Dissel JT, Falkenburg JH, Heemskerk MH.

Haematologica. 2014 Jul;99(7):1255-63. doi: 10.3324/haematol.2013.098830. Epub 2014 Apr 18.

35.

Early cytomegalovirus reactivation leaves a specific and dynamic imprint on the reconstituting T cell compartment long-term after hematopoietic stem cell transplantation.

Lugthart G, van Ostaijen-Ten Dam MM, Jol-van der Zijde CM, van Holten TC, Kester MG, Heemskerk MH, Bredius RG, van Tol MJ, Lankester AC.

Biol Blood Marrow Transplant. 2014 May;20(5):655-61. doi: 10.1016/j.bbmt.2014.01.018. Epub 2014 Jan 23.

36.

A Good Manufacturing Practice procedure to engineer donor virus-specific T cells into potent anti-leukemic effector cells.

van Loenen MM, de Boer R, van Liempt E, Meij P, Jedema I, Falkenburg JH, Heemskerk MH.

Haematologica. 2014 Apr;99(4):759-68. doi: 10.3324/haematol.2013.093690. Epub 2013 Dec 13.

37.

High-throughput identification of antigen-specific TCRs by TCR gene capture.

Linnemann C, Heemskerk B, Kvistborg P, Kluin RJ, Bolotin DA, Chen X, Bresser K, Nieuwland M, Schotte R, Michels S, Gomez-Eerland R, Jahn L, Hombrink P, Legrand N, Shu CJ, Mamedov IZ, Velds A, Blank CU, Haanen JB, Turchaninova MA, Kerkhoven RM, Spits H, Hadrup SR, Heemskerk MH, Blankenstein T, Chudakov DM, Bendle GM, Schumacher TN.

Nat Med. 2013 Nov;19(11):1534-41. doi: 10.1038/nm.3359. Epub 2013 Oct 13.

PMID:
24121928
38.

In vitro generation of mature, naive antigen-specific CD8(+) T cells with a single T-cell receptor by agonist selection.

Snauwaert S, Verstichel G, Bonte S, Goetgeluk G, Vanhee S, Van Caeneghem Y, De Mulder K, Heirman C, Stauss H, Heemskerk MH, Taghon T, Leclercq G, Plum J, Langerak AW, Thielemans K, Kerre T, Vandekerckhove B.

Leukemia. 2014 Apr;28(4):830-41. doi: 10.1038/leu.2013.285. Epub 2013 Oct 4.

PMID:
24091848
39.

Mixed functional characteristics correlating with TCR-ligand koff -rate of MHC-tetramer reactive T cells within the naive T-cell repertoire.

Hombrink P, Raz Y, Kester MG, de Boer R, Weißbrich B, von dem Borne PA, Busch DH, Schumacher TN, Falkenburg JH, Heemskerk MH.

Eur J Immunol. 2013 Nov;43(11):3038-50. doi: 10.1002/eji.201343397. Epub 2013 Aug 25.

40.

Extracellular domains of CD8α and CD8ß subunits are sufficient for HLA class I restricted helper functions of TCR-engineered CD4(+) T cells.

van Loenen MM, Hagedoorn RS, de Boer R, Falkenburg JH, Heemskerk MH.

PLoS One. 2013 May 30;8(5):e65212. doi: 10.1371/journal.pone.0065212. Print 2013.

41.

Characterization of the T-cell-mediated immune response against the Aspergillus fumigatus proteins Crf1 and catalase 1 in healthy individuals.

Jolink H, Meijssen IC, Hagedoorn RS, Arentshorst M, Drijfhout JW, Mulder A, Claas FH, van Dissel JT, Falkenburg JH, Heemskerk MH.

J Infect Dis. 2013 Sep 1;208(5):847-56. doi: 10.1093/infdis/jit237. Epub 2013 May 22.

PMID:
23698813
42.

The human leukocyte antigen-presented ligandome of B lymphocytes.

Hassan C, Kester MG, de Ru AH, Hombrink P, Drijfhout JW, Nijveen H, Leunissen JA, Heemskerk MH, Falkenburg JH, van Veelen PA.

Mol Cell Proteomics. 2013 Jul;12(7):1829-43. doi: 10.1074/mcp.M112.024810. Epub 2013 Mar 12.

43.

Discovery of T cell epitopes implementing HLA-peptidomics into a reverse immunology approach.

Hombrink P, Hassan C, Kester MG, de Ru AH, van Bergen CA, Nijveen H, Drijfhout JW, Falkenburg JH, Heemskerk MH, van Veelen PA.

J Immunol. 2013 Apr 15;190(8):3869-77. doi: 10.4049/jimmunol.1202351. Epub 2013 Mar 8.

44.

Multi-cistronic vector encoding optimized safety switch for adoptive therapy with T-cell receptor-modified T cells.

van Loenen MM, de Boer R, Hagedoorn RS, Jankipersadsing V, Amir AL, Falkenburg JH, Heemskerk MH.

Gene Ther. 2013 Aug;20(8):861-7. doi: 10.1038/gt.2013.4. Epub 2013 Jan 31.

PMID:
23364317
45.

TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo.

Spranger S, Jeremias I, Wilde S, Leisegang M, Stärck L, Mosetter B, Uckert W, Heemskerk MH, Schendel DJ, Frankenberger B.

Blood. 2012 Apr 12;119(15):3440-9. doi: 10.1182/blood-2011-06-357939. Epub 2012 Feb 27.

PMID:
22371883
46.

Notch induces human T-cell receptor γδ+ thymocytes to differentiate along a parallel, highly proliferative and bipotent CD4 CD8 double-positive pathway.

Van Coppernolle S, Vanhee S, Verstichel G, Snauwaert S, van der Spek A, Velghe I, Sinnesael M, Heemskerk MH, Taghon T, Leclercq G, Plum J, Langerak AW, Kerre T, Vandekerckhove B.

Leukemia. 2012 Jan;26(1):127-38. doi: 10.1038/leu.2011.324. Epub 2011 Nov 4.

PMID:
22051534
47.

Identification of a coordinated CD8 and CD4 T cell response directed against mismatched HLA Class I causing severe acute graft-versus-host disease.

Amir AL, Hagedoorn RS, van Luxemburg-Heijs SA, Marijt EW, Kruisselbrink AB, Frederik Falkenburg JH, Heemskerk MH.

Biol Blood Marrow Transplant. 2012 Feb;18(2):210-9. doi: 10.1016/j.bbmt.2011.10.018. Epub 2011 Oct 19.

48.

Allo-HLA-reactive T cells inducing graft-versus-host disease are single peptide specific.

Amir AL, van der Steen DM, Hagedoorn RS, Kester MG, van Bergen CA, Drijfhout JW, de Ru AH, Falkenburg JH, van Veelen PA, Heemskerk MH.

Blood. 2011 Dec 22;118(26):6733-42. doi: 10.1182/blood-2011-05-354787. Epub 2011 Oct 4.

PMID:
21972290
49.

Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer.

Scholten KB, Turksma AW, Ruizendaal JJ, van den Hende M, van der Burg SH, Heemskerk MH, Meijer CJ, Hooijberg E.

J Transl Med. 2011 Sep 5;9:147. doi: 10.1186/1479-5876-9-147.

50.

High-throughput identification of potential minor histocompatibility antigens by MHC tetramer-based screening: feasibility and limitations.

Hombrink P, Hadrup SR, Bakker A, Kester MG, Falkenburg JH, von dem Borne PA, Schumacher TN, Heemskerk MH.

PLoS One. 2011;6(8):e22523. doi: 10.1371/journal.pone.0022523. Epub 2011 Aug 5.

Supplemental Content

Loading ...
Support Center